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Abstract: This is the first prospective population based study to examine risk of 
erectile dysfunction in men with gout in the western world. It reports that following their 
first diagnosis of gout, men have a 31% higher risk of erectile dysfunction than 
matched controls, although the absolute increase in risk is small. Of interest, the 
incidence of erectile dysfunction reported in this study is ten-fold higher than those 
reported in nation-wide cohort studies from Taiwan. There is a need for further 
prospective cohort studies to examine the possible mechanistic association between 
gout, hyperuricaemia and erectile dysfunction.  
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This primary care based prospective cohort study using data from the UK’s Clinical 
Practice Research Datalink (CPRD) reports that following their first diagnosis of gout, 
men have a 31% higher risk of erectile dysfunction (ED) than matched controls, 
although the absolute increase in risk is small (e.g.0.6% for a new consultation for ED, 
and 0.3% for receiving a prescription) reflecting a limited attributable effect on ED 
compared to other factors [1].  
The authors are to be congratulated for undertaking this first prospective population 
based study to examine risk of ED in men with gout in the western world. Only three 
other studies have examined ED in men with gout. One small hospital based USA 
study surveyed people attending rheumatology clinics and reported that 76% of people 
with gout (n=81) had ED compared to 51% of non-gout controls (n=115) [2].  
Interestingly, the incidence rate of ED reported in this CPRD study is ten-fold higher 
than those reported in two nation-wide cohort studies using the National Health 
Insurance Research Database (NHIRD) in Taiwan [3, 4]. It is possible that this 
difference results from cultural reasons or lack of health-insurance cover for ED in 
Taiwan (1). However, hazard ratios for ED in those with gout in the Taiwan studies 
were comparable to the current study [1, 3, 4]. Given the prospective study design and 
source of recruitment we feel that this study provides reasonable estimates of rates of 
ED in men with gout in the western world [1] though the real prevalence is likely to be 
higher because many men may not consult their GP about it. Due to data limitations, 
the authors could not classify ED according to cause.  However, data from the NHIRD 
showed a greater risk of incident organic ED than psychogenic ED in men with gout 
compared to men without gout (odds ratio (95% confidence interval) 1.52(1.03-2.22) 
vs. 1.18(1.03-1.35) respectively) [4] which suggests an important role for 
hyperuricaemia in causing vasculopathy and subsequent ED.    
Sultan et al performed stratified and multivariate analyses to account for several 
confounders that may associate with gout and ED, and used landmark analysis to 
account for survivor bias [1]. Interestingly, they found an elevated risk of ED prior to 
gout diagnosis which suggests that ED may result from hyperuricaemia which 
precedes gout by some years [5]. However, the elevated risk for ED was restricted just 
to the 1-year period prior to gout diagnosis [1]. This suggests a possible delay between 
symptom onset and first consultation for gout, or that Read codes for gout are not 
applied at initial GP consultations, potentially due to diagnostic uncertainty in early 
stages of illness [6]. However, the control group for the analysis of association 
between prior diagnosis of ED and subsequent coding for gout was not selected 
according to the serum uric acid (SUA) and may have undetected hyperuricaemia, 
thereby minimizing the association. Interestingly, a previous CPRD study identified an 
increased risk of many comorbidities that may relate to chronic hyperuricaemia 
(including cardiovascular diseases and depression) in up to 10 years prior to initial 
gout diagnosis and a subsequent increased risk of the same comorbidities in the five 
years following diagnosis [7]. Depression was identified as an association with incident 
and subsequent gout in the current study and could have contributed to an increase 
in psychogenic ED. Thus, there is a need for further prospective cohort studies to 
examine the possible mechanistic association between hyperuricaemia and ED. Given 
that screening for hyperuricaemia is not standard clinical practice in the UK such 
studies cannot be conducted using UK primary care data. 
This study found no protective effect of urate lowering treatment (ULT) on the 
incidence of ED. This is not unexpected as most people with gout in the UK who 
receive ULT are on suboptimal doses and do not achieve target SUAs of < 6 mg/dl [8]. 
Of interest, the authors found a trend towards higher risk of ED in those treated with 
ULT, although this was not statistically significant. This may be due to residual 
confounding by indication, as individuals with more severe disease and comorbidities 
are more likely to receive ULT. Such confounding could have been minimized by 
propensity score matching or adjustment. Thus we feel that the lack of risk reduction 
for incident ED by ULT should not be interpreted as failure of ULT in preventing ED, 
since the suboptimal dosing of allopurinol in the UK is unlikely to exert any beneficial 
effect on vascular health, or indeed mortality [8, 9]. 
In summary, health care professionals should be aware that men with gout are at 
higher risk of ED, and might enquire about this during consultations. Further studies 
are required to determine whether the association between gout and ED is due to 
hyperuricaemia, or if gout confers a higher risk of ED than hyperuricaemia alone.  
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